Venture capital investors showed biopharmaceutical start-ups and growth-stage private companies some love with a trio of $100m-plus financings announced on 14 and 16 February, including a $236m series D round that Kallyope Inc. revealed on Valentine’s Day.
Mega-rounds continue unabated as VC firms continue to invest the billions of dollars in new funds they raised during the past few years, making cash seemingly plentiful for emerging biopharma ventures. (Also see "Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital" - Scrip, 12 February, 2022
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?